

PRESS RELEASE
05 July 2023 15:00:00 CEST



Schelin Catheter® breaking new ground again

Last week, Schelin Catheter® was successfully used at ASST Grande Ospedale Metropolitano Niguarda in Milan, Italy, for yet another minimally invasive method of treating benign prostatic hyperplasia (BPE). Four patients who underwent treatments with iTind™ (Registered trademark of Olympus) received intraprostatic local anesthesia through ProstaLund's injection device prior to treatments.

The Schelin Catheter® has been used for many years as standard before thermotherapy with ProstaLund's own method CoreTherm®. With the Schelin Catheter®, the prostate can be effectively anesthetized in an easy and sterile way. During the last year the device has been used in conjunction with a wide range of other prostate procedures with excellent results.

Last week, Dr Silvia Secco at ASST Grande Ospedale Metropolitano Niguarda in Milan, Italy, performed the world premiere for the Schelin Catheter in conjunction with iTind™ in four BPE-patients. The implants have been in place until today when they were removed.

Dr Silvia Secco: "I have used the Schelin Catheter in conjunction with other methods before, so I already knew the advantages to use it. But the Schelin Catheter usage made a big, big difference compared to my previous iTind cases. There were no patient complaints, and I am very impressed of the results."

Johan Wennerholm, ProstaLund CEO: "I am extremely happy with Dr Secco's world premiere and the results. Our fantastic device continues to exceed the high expectations from the urologists. I am really satisfied that we now have proof of concept for the Schelin Catheter in conjunction with yet another procedure."

*iTind™ is a registered trademark owned by Olympus

For further information, please contact:

Johan Wennerholm, CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com

PRESS RELEASE
05 July 2023 15:00:00 CEST



About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:

Västra Hamnen Corporate Finance AB

Phone: +46 40 200 250

E-mail: ca@vhcorp.se

Attachments

Schelin Catheter® breaking new ground again